Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy

mBio

Volumn 6, Issue 6, 2015, Pages

  Brown, Ashley N ^a   Drusano, George L ^a   Adams, Jonathan R ^a   Rodriquez, Jaime L ^a   Jambunathan, Kalyani ^b   Baluya, Dodge L ^a   Brown, David L ^a   Kwara, Awewura ^c   Mirsalis, Jon C ^b   Hafner, Richard ^d   Louie, Arnold ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MITOCHONDRIAL PROTEIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; HOLLOW FIBER INFECTION MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHARMACODYNAMICS; PRIORITY JOURNAL; TUBERCULOSIS; BIOLOGICAL MODEL; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; MICROBIAL VIABILITY; PRECLINICAL STUDY;

ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LINEZOLID; MICROBIAL VIABILITY; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84952802606     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01741-15     Document Type: Article

References (24)

1. Aziz MA, Wright A, Laszlo A, De MA, Portaels F, Van DA, Wells C, Nunn P, Blanc L, Raviglione M, WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2006. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368:2142-2154.
2. Shah NS, Wright A, Bai G, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13:380-387. http:// dx.doi.org/10.3201/eid1303.061400.
3. Zignol M, Hosseini M, Wright A, Weezenbeek C, Nunn P, Watt C, Williams B, Dye C. 2006. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194:479-485. http://dx.doi.org/10.1086/505877.
4. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon H, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis.NEngl J Med 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
5. De Vriese AS, Coster R, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin J-J, Groote C, Vandecasteele S, Boelaert JR. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111-1117. http://dx.doi.org/10.1086/501356.
6. Nagiec EE, Wu L, Swaney SM, Chosay JG, Ross DE, Brieland JK, Leach KL. 2005. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother 49: 3896-3902. http://dx.doi.org/10.1128/AAC.49.9.3896-3902.2005.
7. Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. 2014. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One 9:e101311-5.
8. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. 2011. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. mBio 2:e00108-11. http://dx.doi.org/10.1371/ journal.pone.0101311.
9. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. 2010. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio 1:e00139-10. http://dx.doi.org/10.1128/mBio.00139-10.
10. Brown AN, Louie A, Adams JR, Jambunathan K, Baluya D, Hafner R, Drusano GL. 2014. Relationship between linezolid (LZD) exposure profiles and toxicity in the hollow fiber infection model (HFIM) system, abstr. A-026b. In Late Breaker Abstr 54th Int Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC.
11. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51: 744-747. http://dx.doi.org/10.1128/AAC.00334-06.
12. Kuter DJ, Tillotson GS. 2001. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 21:1010-1013. http://dx.doi.org/10.1592/phco.21.11.1010.34517.
13. Soriano A, Miró O, Mensa J. 2005. Mitochondrial toxicity associated with linezolid. N Engl J Med 353:2305-2306. http://dx.doi.org/10.1056/ NEJM200511243532123.
14. Saraste M. 1999. Oxidative phosphorylation at the fin de siècle. Science 283:1488-1493. http://dx.doi.org/10.1126/science.283.5407.1488.
15. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P. 2010. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54:4605-4610. http://dx.doi.org/10.1128/AAC.00177-10.
16. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. 2012. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67: 2034-2042. http://dx.doi.org/10.1093/jac/dks153.
17. Wallis R, Jakubiec W, Kumar V, Silvia A, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller P. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 202:745-751. http://dx.doi.org/10.1086/655471.
18. Louie A, Brown D, Files K, Swift M, Fikes S, Drusano GL. 2012. Pharmacodynamics of PNU-10048 (U, sutezolid), a new oxazolidinone, in combination with its active metabolite in the killing of Mycobacterium tuberculosis (Mtb) in an in vitro hollow fiber infection model (HFIM). In Abstr 52nd Int Conf Antimicrob Agents Chemother, 9 to 12 September 2012, San Francisco, CA.
19. McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL. 2009. Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53: 129-135. http://dx.doi.org/10.1128/AAC.00708-08.
20. McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL. 2009. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 53:2375-2381. http://dx.doi.org/ 10.1128/AAC.00167-09.
21. Pfizer Inc. 2000. ZYVOX (linezolid) injection, tablets, and oral suspension: full U.S. prescribing information. Pfizer Inc., New York, NY.
22. Leary R, Jelliffe R, Schumitzky A, Van GuilderM. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389--394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
23. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34:467-476. http://dx.doi.org/ 10.1097/FTD.0b013e31825c4ba6.
24. Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sorgel F, Drusano GL. 2008. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 52:2486-2496. http://dx.doi.org/10.1128/AAC.01439-07.